Glimaday 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately managed by diet and exercise alone. Glimaday 2 Tablet PR is formulated as a prolonged-release tablet to provide a sustained therapeutic effect, improving patient compliance through once-daily dosing. It is recommended to be used alongside lifestyle modifications such as diet and exercise. The medication should be administered under medical supervision with regular monitoring of blood glucose levels, renal function, and potential side effects. Common adverse reactions may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or during pregnancy and lactation. Glimaday 2 Tablet PR offers an effective option for optimizing glycemic control in type 2 diabetes management.

Dosage & How to Use